Inotrem
Targeting TREM-1 to restore immune balance
Paris, France · Founded 2013 · $379.3M raised
- Headquarters
- Paris
- Employees
- 11–50
- Founded
- 2013
- Business Model
- B2B
- Website
- inotrem.com
- Total Funding
- $379.3M
- Last Round
- $150.0M Series COct 2022
- Rounds
- 6
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 6 funding rounds and 10 investors for this company. The full record is or through the API.
About
Inotrem is a French clinical-stage biopharmaceutical company founded in 2013 specializing in immunotherapy for acute and chronic inflammatory syndromes, including sepsis. The company has developed a TREM-1 inhibition platform and lead compound nangibotide, and maintains offices in Paris and a technology center in Nancy, France.
Summary
Inotrem is a Biotech company based in Paris, France, founded in 2013. It has raised $379.3M in total across 6 rounds, most recently a $150.0M Series C round in Oct 2022. Investors include Bpifrance, Prysm Capital and Eurazeo.
Tech & App Stack
7 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Oct 2022
Sign up to see all 6 events
Funding: Series A through Series C. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/inotrem"><img src="https://indexed.vc/api/badge/company/inotrem" alt="Inotrem on Indexed.vc" width="260" height="76" /></a>